Improved Personalized Cancer Immunotherapy


Scientists at NIH have identified a process to select highly tumor-reactive T cells from a patient tumor sample based on the expression of four specific T cell surface markers: programmed cell death protein 1 (PD-1; CD279), 4-1BB (CD137), T cell lg-and mucin-domain-containing molecule-3 (TIM-3), and/or lymphocyte activation gene 3 (LAG-3). After this enriched population of tumor fighting T cells, primarily tumor infiltrating lymphocytes (TIL), is selected and expanded to large quantities, it gets re-infused into the patient via an adoptive cell transfer (ACT) regimen. The key finding for this process is that the most tumor-reactive TIL found in a bulk population of cells obtained from a patient tumor sample reliably exhibit high expression of one or more of these four markers.

By selecting cancer attacking TIL from a patient's tumor based on these markers prior to re-infusion, in vitro culture time is reduced to grow up the desired T cells and a more effective anti-cancer T cell product can be produced. In comparison to previous TIL immunotherapy approaches, this new method for selecting tumor-reactive T cells/TIL from tumor samples should help TIL immunotherapy become more GMP compliant and allow greater standardized of the TIL production process to enable more widespread utilization of this personalized cancer treatment approach outside of NIH.



Potential Commercial Applications: Competitive Advantages:
  • Personalized ACT immunotherapy to treat human cancers using T cells obtained from a tumor sample
  • Possible integration into a standard procedure for obtaining tumor-reactive T cells/TIL from a tumor as part of a GMP-compliant TIL manufacturing process that gains regulatory approval as a personalized cancer treatment option
  • The immunotherapy component of a combination cancer therapy cancer regiment targeting specific tumor antigens in individual patients
  • More rapid tumor-reactive T cell culturing process for laboratory testing
 
  • Simpler: Tumor-reactive T cells/TIL can be selected for ACT from a bulk population derived from a tumor sample using common laboratory techniques
  • More rapid: Selection of T cells/TIL based on expression of specific cell surface markers will reduce the culture time for these T cells before infusion into the patient to fight the tumor
  • Less screening: This selection method eliminates the need to screen T cells/TIL for autologous tumor recognition before re-infusion into the patient


Development Stage:
Discovery (Lead Identification)

Related Invention(s):
E-085-2013
E-273-2009
E-275-2002


Inventors:

Steven Rosenberg (NCI)  ➽ more inventions...


Intellectual Property:
US Application No. 61/771,247
Foreign Filed Application No. PCT/US13/38799

Collaboration Opportunity:

Licensing only


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-059-2013
Updated: Mar 9, 2018